Pfizer, CStone Score China's Seventh Immuno-Oncology Approval
Cejemly To Enter Crowded Market
Latest approval gives major US drug maker new foothold in China’s heated and increasingly crowded PD-1 immuno-oncology race.
Latest approval gives major US drug maker new foothold in China’s heated and increasingly crowded PD-1 immuno-oncology race.